Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia

Frontiers in Pediatrics - Switzerland
doi 10.3389/fped.2015.00070
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

A United Kingdom Immune Thrombocytopenia (ITP) Forum Review of Practice: Thrombopoietin Receptor Agonists

British Journal of Haematology
Hematology
2016English

The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia

European Oncology and Haematology
OncologyHematology
2011English

Thrombopoietin Receptor Agonists for the Treatment of Inherited Thrombocytopenia

Haematologica
Hematology
2020English

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2017English

Autologous 111 Indium‐oxinate‐labelled Platelet Sequestration Study in Patients With Immune Thrombocytopenia Treated by Thrombopoietin Receptor‐agonists

British Journal of Haematology
Hematology
2019English

Switching Thrombopoietin Receptor Agonist Treatments in Patients With Primary Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2019English

Deciphering Predictive Factors for Choice of Thrombopoietin Receptor Agonist, Treatment Free Responses, and Thrombotic Events in Immune Thrombocytopenia

Scientific Reports
Multidisciplinary
2019English

Eltrombopag: An Update on the Novel, Non-Peptide Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia

Annals of Hematology
MedicineHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy